Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
US6855802B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 22, 1999 |
| Grant date | Feb 15, 2005 |
| Priority date | — |
| Expiry date | Apr 22, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a method for identifying peptide compounds derived from hsp70, having at least one mutation relative to the hsp70 natural sequence, said compounds bringing about a response T specific of tumours, and the peptide compounds obtainable by said method. The invention also concerns the use of said peptide compounds for performing repeated immunization in a subject so as to interrupt immune tolerance for the corresponding natural (non-mutated) peptide. Said peptide compounds are useful for preparing a medicine designed in particular for treating cancer optionally in combination with any agent provoking tumour cell stress.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.